


Hepatology COVID -19 Registry
Week 3 Report

6 new cases added to the report since last week


	Chronic liver disease (N=9)	Post-liver transplantation (N=8)
Gender (%)	Female = 4 (44.5%) Male = 5 (55.5%)	Female = 4 (50%) Male = 4 (50%)
Median Age (yr) at time of COVID diagnosis (range)	5 (0.25-15)	12 (1-21)
Etiology of liver disease	Biliary atresia = 4 Autoimmune hepatitis = 1 NAFLD = 2 Idiopathic Cholestasis = 1 Metabolic disorder = 1	Biliary atresia = 4 Acute liver failure = 2 Metabolic disorders = 1 Tumor=1
Highest level of care		
Outpatient	3	6
Hospital floor	5	2
ICU	1	0
Immunosuppression at time of COVID diagnosis (*some patients were on multiple agents)	Azathioprine = 1 No Immunosuppression = 8	Tacrolimus = 6 Sirolimus = 1 Steroids = 3 Mycophenolate Mofetil = 4 Cyclosporine =1
Specific Treatment for COVID (*some patients were on multiple agents)	Hydroxychloroquine + Azithromycin = 2 IVIG =1 Tocilizumab and Sarilumab = 1	Azithromycin : 1
Highest respiratory support		
None	6	7
Nasal cannula/CPAP/BiPAP	1	0
Mechanical ventilation	1	0
Pending information	1	1
Final clinical outcome		
Death	0	0
Recovery	7	6
Still active in clinical course	1	1
Pending information	1	1
Liver related Complications	Ascites= 3 Portal Hypertension Bleeding =1 None = 5	None = 7

Presenting symptoms at time of diagnosis




* Other symptoms reported: Malaise, reduced oral intake

Baseline ALT levels (CLD + Post LT group)



* Red dot denotes median, blue dots individual levels (Median ALT 37, range 19-200)


Change done to Immunosuppressive agent (Post LT group)



*Stopped, decreased the dose, others and No changes

Commonest agent **stopped**: Mycophenolate Mofetil

Peak ALT Levels (CLD + Post LT Group)



*Red dot denotes median, blue dots individual values (Median ALT 95, range 20-424)